Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Query: "AREA[SponsorSearch](Idera Pharmaceuticals, Inc.)"
Count: 15
Selected: 0
NCT03865082Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
NCT03445533A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma
NCT03052205A Study of Intratumoral IMO-2125 in Patients With Refractory Solid Tumors
NCT02644967A Phase 2 Study to Assess the Safety and Efficacy of IMO-2125 With 8 mg Ipilimumab in Patients With Metastatic Melanoma
NCT02612857Trial of IMO-8400 in Adult Patients With Dermatomyositis
NCT02363439Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401
NCT02252146Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation
NCT02092909Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
NCT01899729A 12-week Dose-Ranging Trial in Patients With Moderate to Severe Plaque Psoriasis
NCT01622348Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
NCT00990938Study of Combination Treatment With IMO-2125 and Ribavirin in Naïve Hepatitis C-infected, Genotype 1 Patients
NCT00729053Study of IMO-2055 in Metastatic or Locally Recurrent Clear Cell Renal Carcinoma
NCT00728936Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
NCT04196283A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
NCT04126876A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma